1 |
Karin M. Mitogen-activated protein kinase cascades as regulators of stress responses. Ann N Y Acad Sci. 1998;30:139-146. https://doi.org/10.1111/j.1749-6632.1998.tb08987.x
|
2 |
Wang X, Martindale JL, Holbrook NJ. Requirement for ERK activation in cisplatin-induced apoptosis. J Biol Chem. 2000;275:39435-39443. https://doi.org/10.1074/jbc.M004583200
|
3 |
Tang MK, Zhou HY, Yam JW, Wong AS. c-Met over expression contributes to the acquired apoptotic resistance of nonadherent ovarian cancer cells through a cross talk mediated by phosphatidylinositol 3-kinase and extracellular signal-regulated kinase 1/2. Neoplasia. 2010;12:128-138. https://doi.org/10.1593/neo.91438
|
4 |
Park SJ, Kim IS. The role of p38 MAPK activation in auranofin-induced apoptosis of human promyelocytic leukaemia HL-60 cells. Br J Pharmacol. 2005;146:506-513. https://doi.org/10.1038/sj.bjp.0706360
DOI
|
5 |
Wagner EF, Nebreda AR. Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer. 2009;9:537-549. https://doi.org/10.1038/nrc2694
DOI
|
6 |
Bulavin DV, Fornace AJ. p38 MAP kinase's emerging role as a tumor suppressor. Adv Cancer Res. 2004;92:95-118. https://doi.org/10.1016/S0065-230X(04)92005-2
DOI
|
7 |
Chang L, Karin M. Mammalian MAP kinase signalling cascades. Nature. 2001;410:37-40. https://doi.org/10.1038/35065000
DOI
|
8 |
Johnson GL, Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science. 2002;298:1911-1912. https://doi.org/10.1126/science.1072682
DOI
|
9 |
Ip YT, Davis RJ. Signal transduction by the c-Jun N-terminal kinase (JNK)-from inflammation to development. Curr Opin Cell Biol. 1998;10:205-219. https://doi.org/10.1016/s0955-0674(98)80143-9
DOI
|
10 |
Frezza M, Hindo S, Chen D, Davenport A, Schmitt S, Tomco D, et al. Novel metals and metal complexes as platforms for cancer therapy. Curr Pharm Des. 2010;16:1813-1825. https://doi.org/10.2174/138161210791209009
|
11 |
Cohen TT. Apoptosis. Immunol. 1993;14:126-130. https://doi.org/10.1016/0167-5699(93)90214-6
|
12 |
Chen D, Milacic V, Frezza M, Dou QP. Metal complexes, their cellular targets and potential for cancer therapy. Curr Pharm Des. 2009;15:777-791. https://doi.org/10.2174/138161209787582183
|
13 |
Goldstein P. Controlling cell death. Science. 1997;275:1081-1082. https://doi.org/10.1126/science.275.5303.1081
DOI
|
14 |
Yuan ZQ, Sun M, Feldman RI, Wang G, Ma X, Jiang C, et al. Frequent activation of AKT2 and induction of apoptosis by inhibition of phosphoinositide-3-OH kinase/Akt pathway in human ovarian cancer. Oncogene. 2000;19:2324-2330. https://doi.org/10.1038/sj.onc.1203598
DOI
|
15 |
Salvesen GS, Abrams JM. Caspase activation-stepping on the gas or releasing the brakes? Lessons from humans and flies. Oncogene. 2004;23:2774-2784. https://doi.org/10.1038/sj.onc.1207522
DOI
|
16 |
Elmore S. Apoptosis: a review of programmed cell death. Toxicol Pathol. 2007;35:495-516. https://doi.org/10.1080/01926230701320337
DOI
|
17 |
Kaufmann SH, Desnoyers S, Ottaviano Y, Davidson NE, Poirier GG. Specific proteolytic cleavage of poly (ADP-ribose) polymerase: an early marker of chemotherapy-induced apoptosis. Cancer Res. 1993;53:3976-3985.
|
18 |
Muscella A, Calabriso N, Fanizzi FP, De Pascali SA, Urso L, Ciccarese A, et al. Pt [(O,O'-acac)(gamma-acac)(DMS)], a new Pt compound exerting fast cytotoxicity in MCF-7 breast cancer cells via the mitochondrial apoptotic pathway. Br J Pharmacol. 2008;153:34-49. https://doi.org/10.1038/sj.bjp.0707576
DOI
|
19 |
Hail N Jr, Lotan R. Cancer chemoprevention and mitochondria: targeting apoptosis in transformed cells via the disruption of mitochondrial bioenergetics/redox state. Mol Nutr Food Res. 2009;53:49-67. https://doi.org/10.1002/mnfr.200700527
DOI
|
20 |
Siddik ZH. Cisplatin: mode of cytoxic action and molecular basis of resistance. Oncogene. 2003;22:7265-7279. https://doi.org/10.1038/sj.onc.1206933
DOI
|
21 |
Fulda S, Debatin KM. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene. 2006;25:4798-4811. https://doi.org/10.1038/sj.onc.1209608
DOI
|
22 |
Cho KR, Shih IeM. Ovarian cancer. Annu Rev Pathol. 2009;4:287-313. https://doi.org/10.1146/annurev.pathol.4.110807.092246
DOI
|
23 |
Chen G, Gong M, Yan M, Zhang X. Sevoflurane induces endoplasmic reticulum stress mediated apoptosis in hippocampal neurons of aging rats. PLoS ONE. 2013;8:E57870. https://doi.org/10.1371/journal.pone.0057870
|
24 |
Salvesen GS, Dixit VM. Caspases: intracellular signaling by proteolysis. Cell. 1997;91:443-446. https://doi.org/10.1016/s0092-8674(00)80430-4
DOI
|
25 |
Qian W, Nishikawa M, Haque AM, Hirose M, Mashimo M, Sato E, et al. Mitochondrial density determines the cellular sensitivity to cisplatin-induced cell death. Am J Physiol Cell Physiol. 2005;289:C1466-1475. https://doi.org/10.1152/ajpcell.00265.2005
|
26 |
Brazil DP, Hemmings BA. Ten years of protein kinase B signalling: a hard Akt to follow. Trends Biochem Sci. 2001;26:657-664. https://doi.org/10.1016/s0968-0004(01)01958-2
DOI
|
27 |
Swisher EM, Taniguchi T, Karlan BY. Molecular scores to predict ovarian cancer outcomes: a worthy goal, but not ready for prime time. J Natl Cancer Inst. 2012;104:642-645. https://doi.org/10.1093/jnci/djs203
|
28 |
Kwon HW, Lee DH. The Inhibitory effects of cordycepin on phosphoproteins including PI3K, Akt, and p38. Korean J Clin Lab Sci. 2017;49:99-107. https://doi.org/10.15324/kjcls
|
29 |
Achkar IW, Abdulrahman N, Al-ulaiti H. Joseph JM, Uddin S, Mraiche F. Cisplatin based therapy: the role of the mitogen activated protein kinase signaling pathway. J Transl Med. 2018;16:96. https://doi.org/10.1186/s12967-018-1471-1
DOI
|
30 |
Smolle E, Taucher V, Pichler M, Petru E, Lax S, Haybaeck J. Targeting signaling pathways in epithelial ovarian cancer. Int J Mol Sci. 2013;14:9536-9555. https://doi.org/10.3390/ijms14059536
DOI
|
31 |
Lasky T, Silbergeld E. P53 mutations associated with breast, colorectal, liver, lung, and ovarian cancers. Environ Health Perspect. 1996;104:1324-1331. https://doi.org/10.1289/ehp. 961041324
DOI
|
32 |
Kulik G, Weber MJ. Akt-dependent and -independent survival signaling pathways utilized by insulin-like growth factor I. Mol Cell Biol. 1998;18:6711-6718. https://doi.org/10.1128/mcb.18.11.6711
DOI
|
33 |
Stambolic V, Suzuki A, de la Pompa JL, Brothers GM, Mirtsos C, Sasaki T, et al. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell. 1998;95:29-39. https://doi.org/10.1016/s0092-8674(00)81780-8
DOI
|
34 |
Siegel RL, Miller KD, Jemal A. Cancer statistics. CA Cancer J Clin. 2018;68:7-30. https://doi.org/10.3322/caac.21442
|
35 |
Gu J, Tamura M, Yamada KM. Tumor suppressor PTEN inhibits integrin-and growth factor-mediated mitogen-activated protein (MAP) kinase signaling pathways. J Cell Biol. 1998;143:1375-1383. https://doi.org/10.1083/jcb.143.5.1375
DOI
|